News

Published on 30 Nov 2023 on Simply Wall St. via Yahoo Finance

Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago


Article preview image

We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits us in the gut when we see fellow investors suffer a loss. For example, we sympathize with anyone who was caught holding SCYNEXIS, Inc. (NASDAQ:SCYX) during the five years that saw its share price drop a whopping 77%. And it's not just long term holders hurting, because the stock is down 34% in the last year. Furthermore, it's down 56% in about a quarter. That's not much fun for holders. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.

Check out our latest analysis for SCYNEXIS

NASDAQ.SCYX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago

We're definitely into long term investing, but some companies are simply bad investments over any...

Simply Wall St. via Yahoo Finance 30 Nov 2023

SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?

SCYNEXIS' (NASDAQ:SCYX) stock is up by a considerable 18% over the past three months. As most wou...

Simply Wall St. via Yahoo Finance 12 Sep 2023

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why

SCYNEXIS’ SCYX shares have surged 133.6% year to date against the industry's 1.9% decline. <img a...

Zacks via Yahoo Finance 4 Sep 2023

Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates

Avalo Therapeutics, Inc. (AVTX) came out with a quarterly loss of $0.59 per share versus the Zack...

Zacks via Yahoo Finance 3 Aug 2023

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

Scynexis (SCYX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Esti...

Zacks via Yahoo Finance 11 May 2023

SCYNEXIS, Inc.'s (NASDAQ:SCYX) largest shareholders are individual investors with 51% ownership,...

Key Insights The considerable ownership by individual investors in SCYNEXIS indicates that they c...

Simply Wall St. via Yahoo Finance 8 May 2023

We Might See A Profit From SCYNEXIS, Inc. (NASDAQ:SCYX) Soon

SCYNEXIS, Inc. (NASDAQ:SCYX) is possibly approaching a major achievement in its business, so we w...

Simply Wall St. via Yahoo Finance 12 Apr 2023

Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

Shares of Scynexis SCYX surged almost 76% on Mar 30, after it entered an exclusive license agreem...

Zacks via Yahoo Finance 31 Mar 2023

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.43%

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.43%

Investing.com 30 Mar 2023

SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain...

Some of the losses seen by insiders who purchased US$236k worth of SCYNEXIS, Inc. (NASDAQ:SCYX) s...

Simply Wall St. via Yahoo Finance 22 Mar 2023